Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer

被引:29
作者
Imawari, Yoshimi [1 ,2 ]
Mimoto, Rei [2 ]
Hirooka, Shinichi [3 ]
Morikawa, Toshiaki [2 ]
Takeyama, Hiroshi [2 ]
Yoshida, Kiyotsugu [1 ]
机构
[1] Jikei Univ, Dept Biochem, Sch Med, Tokyo, Japan
[2] Jikei Univ, Dept Surg, Sch Med, Tokyo, Japan
[3] Jikei Univ, Dept Pathol, Sch Med, Tokyo, Japan
关键词
breast cancer; cyclin-dependent kinase 14; dual-specificity tyrosine-regulated kinase 2; invasion; proliferation; EPITHELIAL-MESENCHYMAL-TRANSITION; DYRK2; EXPRESSION; PROSTATE-CANCER; DNA-DAMAGE; PFTK1; PHOSPHORYLATION; CHEMOTHERAPY; SUPPRESSOR; MARKER; OVEREXPRESSION;
D O I
10.1111/cas.13459
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor progression is the main cause of death in patients with breast cancer. Accumulating evidence suggests that dual-specificity tyrosine-regulated kinase 2 (DYRK2) functions as a tumor suppressor by regulating cell survival, differentiation, proliferation and apoptosis. However, little is known about the mechanisms of transcriptional regulation by DYRK2 in cancer progression, particularly with respect to cancer proliferation and invasion. Here, using a comprehensive expression profiling approach, we show that cyclin-dependent kinase 14 (CDK14) is a target of DYRK2. We found that reduced DYRK2 expression increases CDK14 expression, which promotes cancer cell proliferation and invasion invitro, in addition to tumorigenicity invivo. CDK14 and DYRK2 expression inversely correlated in human breast cancer tissues. We further identified androgen receptor (AR) as a candidate of DYRK2-dependent transcription factors regulating CDK14. Taken together, our findings suggest a mechanism by which DYRK2 controls CDK14 expression to regulate tumor cell proliferation and invasion in breast cancer. Targeting of this pathway may be a promising therapeutic strategy for treating breast cancer.
引用
收藏
页码:363 / 372
页数:10
相关论文
共 30 条
[1]   Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target [J].
Chen, Yu ;
Clegg, Nicola J. ;
Scher, Howard I. .
LANCET ONCOLOGY, 2009, 10 (10) :981-991
[2]   Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study [J].
Collins, Laura C. ;
Cole, Kimberly S. ;
Marotti, Jonathan D. ;
Hu, Rong ;
Schnitt, Stuart J. ;
Tamimi, Rulla M. .
MODERN PATHOLOGY, 2011, 24 (07) :924-931
[3]   Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer [J].
Enomoto, Yasuko ;
Yamashita, Shin-ichi ;
Yoshinaga, Yasuteru ;
Fukami, Yasuyoshi ;
Miyahara, So ;
Nabeshima, Kazuki ;
Iwasaki, Akinori .
TUMOR BIOLOGY, 2014, 35 (11) :11021-11025
[4]   Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis [J].
Forouzanfar, Mohammad H. ;
Foreman, Kyle J. ;
Delossantos, Allyne M. ;
Lozano, Rafael ;
Lopez, Alan D. ;
Murray, Christopher J. L. ;
Naghavi, Mohsen .
LANCET, 2011, 378 (9801) :1461-1484
[5]   Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer [J].
Gu, Xiaoling ;
Wang, Yingying ;
Wang, Hua ;
Ni, Qichao ;
Zhang, Chunhui ;
Zhu, Jia ;
Huang, Wei ;
Xu, Pan ;
Mao, Guoxin ;
Yang, Shuyun .
MEDICAL ONCOLOGY, 2015, 32 (07)
[6]   Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis [J].
Guo, Xing ;
Wang, Xiaorong ;
Wang, Zhiping ;
Banerjee, Sourav ;
Yang, Jing ;
Huang, Lan ;
Dixon, Jack E. .
NATURE CELL BIOLOGY, 2016, 18 (02) :202-+
[7]   Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer [J].
Ito, Daisuke ;
Yogosawa, Satomi ;
Mimoto, Rei ;
Hirooka, Shinichi ;
Horiuchi, Takashi ;
Eto, Ken ;
Yanaga, Katsuhiko ;
Yoshida, Kiyotsugu .
CANCER SCIENCE, 2017, 108 (08) :1565-1573
[8]   Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer A Review [J].
Kono, Miho ;
Fujii, Takeo ;
Lim, Bora ;
Karuturi, Meghan Sri ;
Tripathy, Debasish ;
Ueno, Naoto T. .
JAMA ONCOLOGY, 2017, 3 (09) :1266-1273
[9]   A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility [J].
Leung, W. K. C. ;
Ching, A. K. K. ;
Chan, A. W. H. ;
Poon, T. C. W. ;
Mian, H. ;
Wong, A. S. T. ;
To, K-F ;
Wong, N. .
ONCOGENE, 2011, 30 (44) :4464-4475
[10]  
Miller CT, 2003, CANCER RES, V63, P4136